The orexin receptor antagonist lemborexant (Dayvigo) has been approved by the US Food and Drug Administration for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults, Eisai Co. announced.
A secondary analysis of a study investigating adjunctive pimavanserin for the treatment of patients with major depressive disorder found that it significantly improved insomnia and sleepiness, researchers reported at Psych Congress 2020.
Poor sleep may be linked to a greater risk for poor mental health on college campuses, new research suggests. With each night of insufficient sleep, the risk of mental health symptoms increased by roughly 20%.
NEW YORK—Cognitive-behavioral therapy (CBT) delivered by video call appears to inspire as much confidence among patients with insomnia as does the traditional face-to-face approach, according to preliminary research.